← Back to Search

CAR T-cell Therapy

CTX131 for Blood Cancers

Phase 1 & 2
Recruiting
Research Sponsored by CRISPR Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
≥18 years of age
Diagnosed with r/r T Cell Lymphoma (TCL), B Cell Lymphoma (BCL), or Acute Myeloid Leukemia (AML) meeting specified criteria
Must not have
History or presence of clinically relevant CNS pathology
Prior treatment with anti-CD70 targeting agents
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from ctx131 infusion up to 60 months post-infusion
Awards & highlights

Summary

This trial is testing a new treatment called CTX131 in patients with a type of blood cancer that has come back or not responded to previous treatments. The study will look at how safe and effective CT

Who is the study for?
This trial is for adults with certain blood cancers that have come back or didn't respond to treatment. These include various types of lymphoma and acute myeloid leukemia. Participants must meet specific health criteria not detailed here.
What is being tested?
The study is testing CTX131, a new potential treatment for blood cancers. It's an open-label trial, meaning everyone knows they're getting the drug, and it aims to find out how safe it is and how well it works at different doses.
What are the potential side effects?
Specific side effects of CTX131 are not listed but may include typical reactions seen in cancer treatments such as fatigue, nausea, immune system impacts, infusion-related reactions, and others based on similar therapies.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have been diagnosed with a specific type of blood cancer.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a significant brain or nervous system condition.
Select...
I have been treated with drugs targeting CD70.
Select...
My cancer has spread to my brain.
Select...
I have an immune system disorder that requires steroids or other treatments.
Select...
I have had a solid organ or bone marrow transplant that meets certain criteria.
Select...
I do not have any ongoing serious infections.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from ctx131 infusion up to 60 months post-infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and from ctx131 infusion up to 60 months post-infusion for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Composite Complete Remission (CRc)
Objective Response rate (ORR)
Phase 1 Part A (dose escalation) and Part B (dose optimization in selected disease types)

Trial Design

1Treatment groups
Experimental Treatment
Group I: CTX131Experimental Treatment1 Intervention
Administered by IV infusion following lymphodepleting chemotherapy

Find a Location

Who is running the clinical trial?

CRISPR TherapeuticsLead Sponsor
6 Previous Clinical Trials
306 Total Patients Enrolled
~193 spots leftby May 2030
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top